# **COVAX DATA BRIEF**

December 08, 2023

## SUPPLY

### **CUMULATIVE TOTAL NUMBER OF DOSES**

Allo	ocation	

Shipped



**89**% of COVAX doses delivered have been to AMC participants

Last update: November 28, 2023



54 countries representing 58% of total AMC91 population

Last update: November 20, 2023

DEMAND



of supply in LICs are COVAX doses

Last update: November 20, 2023



of AMC participants for whom COVAX represents over 70% supply

24 countries representing 26% of the total AMC91 population

Last update: November 20, 2023

<b>1,055m</b> APA	<b>53</b> %	
	<b>926m</b> donations	47

### **CUMULATIVE TOTAL**

Vaccine products	Allocation*	Shipped	No. countries
Pfizer-BioNTech	550m	549m	115
J&J	318m	316m	68
Covishield (SII/AZ)	292m	292m	49
AstraZeneca	290m	288m	127
Moderna	189m	187m	43
Sinovac	133m	118m	21
Sinopharm	115m	115m	34
Pfizer-BioNTech Pediatric	82m	81m	31
Pfizer-BioNTech VCV	35m	32m	29
Novavax	2.3m	1.8m	1

To date: November 28, 2023 \* Allocation after any adjustment



of doses have been offered (in terms of volume) against completed country requests through rolling allocation process

Last update: September 01, 2023

## COVERAGE



**COVAX** deliveries to AMCs expected in 2023

Last update: November 28, 2023



2.01BN

**1.98**BN



#### doses requested for the COVID-19 vaccine programme in 2024

Last update: November 28, 2023 Final total number of doses approved will be confirmed in December



### **TRACKING LOWER-INCOME COUNTRIES' PROGRESS**

Number of AMC countries with less than 10% primary series coverage



AMC92	63%	<b>57</b> %	84%	<b>72%</b>	88%	17%	30%
AMC91	56%	<b>49</b> %	77%	<b>62</b> %	88%	17%	44%**
LICs	35%	<b>29</b> %	<b>65</b> %	<b>39</b> %	81%	5%	<b>74</b> %
LMICs	69%	<b>62</b> %	<b>89</b> %	<b>78</b> %	89%	20%	38%**
UMICs	81%	77%	<b>92</b> %	86%	93%	46%	3%
HICs	81%	<b>76</b> %	89%	<b>92</b> %	94%	49%	0%

adults booster AMC HCWs

booster

\* The denominator for each group is dependent upon the number of countries reporting uptake in these coverage groups (i.e. Only 72 of the 92 AMCs are reporting HCW uptake) \*\* This percentage excludes India.

The % of deliveries from COVAX is reported from November 20, 2023.

Cumulative for all sources as of November 24, 2023.

## ADMINISTRATION

### **IMPACT**

### 2.7м estimated COVID-19

deaths prevented by **COVAX**-supported vaccines as of end 2022

These estimates are fitted against excess mortality and are subject to further refinement.







**COVID** funds committed by Gavi

Last update: October 31, 2023



**AMCs have received** approval for COVID-19 delivery funding

Last update: November 28, 2023

Funding goes beyond EA+NBF+CD3 and includes additional funding streams

### **AMC COUNTRIES, ALL SOURCES**

**5.1**BN **Total doses administered** 

Cumulative as of: November 23, 2023

#### % delivered doses utilised

Last update: November 28, 2023



Last update: November 23, 2023

\* These amounts (in US\$) reflect the total funding for Early Access, Needs-based and CDS3 that has been thus far approved.

## **COVAX PORTFOLIO** ADVANCE PURCHASE AGREEMENTS (APAS)

Status of advance purchase agreements

#### AstraZeneca



#### - - - -. (- - **a b**)

AMC price per dose (US\$)	Covid Vaccine	ne	
Supplier Name	2021	2022	2023
Beijing Institute of Biological Products Co (China)	\$5.50	\$5.50	
Sinovac Life Sciences Co. (China)	*	*	
Janssen Pharmaceutica NV (Belgium)	\$7.50	\$7.50	\$7.50
Pfizer Overseas LLC (USA)	*	*	*
AstraZeneca (UK)	\$4.00	\$4.00	
Moderna Switzerland GMbH	\$10.00	\$7.00	
Novavax, Inc. (USA)	*	*	
Serum Life Sciences, multiple products (UK)	\$3.00	\$3.00	

unicef 🔮 CEPI

Total docos CDC funding

WHO region	countries	administered	breakdown*
SEARO	10	3,220m	\$78m
EMRO	11	589m	\$215m
AFRO	40	596m	\$657m
WPRO	15	527m	\$44m
e Euro	6	142m	\$31m
PAHO	10	62m	\$28m

Clover	Novavax
Covishield (SII/AZ)	Pfizer APA 1
Covovax (SII/NVX)	Pfizer APA 2
J&J	Sinopharm
Moderna APA 1	Sinovac
In progress	Completed
Nearing completion	Terminated Last update: December 08, 2023



Percentage above is the median among AMCs. Note, given in-country stock

and expected wastage, utilisation rate is unlikely to ever reach 100

Final above-country expiry % through **COVAX APAs** and donation commitments

**Current expiries** 

Last update: December 08, 2023

\* Supplier has not agreed to the publication of prices. As of: November 28, 2023 Full UNICEF COVID-19 vaccine price data: (Resource 7)

## **COVAX PORTFOLIO** DONATIONS





#### total donations

Last update: November 28, 2023 Enumeration of total doses donated may be subject to change given evolving methodology.





donor countries

Last update: November 28, 2023 The number of donor countries for whom shipments have been received by the recipient country.



recipient countries

Last update: November 28, 2023



Gavi (

Donation volume, by product							
Pfizer-BioNTech	43%						
		1&1	27%	6			
				AstraZeneca	17%		
						Moderna	<b>13</b> %

Last update: November 28, 2023



This COVAX data brief is produced by Gavi, the Vaccine Alliance's Office of the COVAX Facility, based on data from CEPI, WHO, and UNICEF. Coverage Equity graphic data source:



